{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:12:33Z","timestamp":1791087153020,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.mayocp.2012.04.011","type":"journal-article","created":{"date-parts":[[2012,7,13]],"date-time":"2012-07-13T16:08:55Z","timestamp":1342195735000},"page":"739-745","source":"Crossref","is-referenced-by-count":165,"title":["Vasculitis Associated With Tumor Necrosis Factor-\u03b1 Inhibitors"],"prefix":"10.1016","volume":"87","author":[{"given":"Olayemi","family":"Sokumbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashima","family":"Makol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2012.04.011_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1196\/annals.1361.100","article-title":"Autoimmunity and anti-TNF-\u03b1 agents","volume":"1051","author":"Atzeni","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mayocp.2012.04.011_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.091463","article-title":"Tumor necrosis factor and anti-tumor necrosis factor therapies","volume":"85","author":"Keystone","year":"2010","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"10.1016\/j.mayocp.2012.04.011_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.sder.2006.12.002","article-title":"Complications and adverse reactions in the use of newer biologic agents","volume":"26","author":"Callen","year":"2007","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.mayocp.2012.04.011_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncprheum0708","article-title":"Drug insight: autoimmune effects of medications: what's new?","volume":"4","author":"Mongey","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2012.04.011_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2008.10.060","article-title":"Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review","volume":"61","author":"Moustou","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.mayocp.2012.04.011_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/09546630410017275","article-title":"A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab","volume":"15","author":"Scheinfeld","year":"2004","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.mayocp.2012.04.011_bib7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.annder.2009.10.003","article-title":"Paradoxical cutaneous manifestations during anti-TNF-alpha therapy [in French]","volume":"137","author":"Viguier","year":"2010","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.mayocp.2012.04.011_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.mayocp.2012.04.011_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2012.04.011_bib10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","article-title":"Vasculitides induced by TNF\u03b1 antagonists: a study in 39 patients in France","volume":"73","author":"Saint Marcoux","year":"2006","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.mayocp.2012.04.011_bib11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2012.04.011_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.5021\/ad.2011.23.4.432","article-title":"Causality assessment of cutaneous adverse drug reactions","volume":"23","author":"Son","year":"2011","journal-title":"Ann Dermatol"},{"issue":"3","key":"10.1016\/j.mayocp.2012.04.011_bib13","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.mayocp.2012.04.011_bib14","first-page":"1955","article-title":"Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents","volume":"31","author":"Mohan","year":"2004","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2012.04.011_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.mayocp.2012.04.011_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0025-6196(11)60668-X","article-title":"Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic","volume":"84","author":"Wetter","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"3, suppl 49","key":"10.1016\/j.mayocp.2012.04.011_bib17","first-page":"S23","article-title":"Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients: a systematic review of 2707 patients, 18 vasculitis","volume":"26","author":"Guignard","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.mayocp.2012.04.011_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/ar2341","article-title":"The role of tumor necrosis factor-alpha in systemic lupus erythematosus","volume":"10","author":"Aringer","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2012.04.011_bib19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","article-title":"Tumor necrosis factor inhibitor-associated dermatomyositis","volume":"146","author":"Klein","year":"2010","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.mayocp.2012.04.011_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/archderm.143.2.233","article-title":"The yin and yang of TNF-\u03b1 inhibition","volume":"143","author":"Fiorentino","year":"2007","journal-title":"Arch Dermatol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612005605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612005605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:22:06Z","timestamp":1542846126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619612005605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0025619612005605"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2012.04.011","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}